IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States
CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.
Third Quarter 2026 Operational and Clinical Highlights
"We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®," said Eyal Shamir, Chief Executive Officer of IceCure Medical.
ChoICE Study Moving Forward:
Subsequent to the end of the third quarter of 2026, IceCure announced additional progress in its ChoICE Study:
Additional Third Quarter of 2026 Successes:
Financial Results for the Nine Months Ended September 30, 2026
Total revenues for the nine months ended September 30, 2026 increased approximately 26% to $2.6 million, compared to $2.1 million for the corresponding period in 2025.
Gross profit for the nine months ended September 30, 2026 increased approximately 22% to $762,000, compared to $626,000 in the corresponding period of 2025.
Research and development expenses for the nine months ended September 30, 2026 were $6.5 million, compared to $5.1 million in the corresponding period of 2025, primarily reflecting increased expenses related to the ChoICE Study and other clinical and development activities.
Sales and marketing expenses were $3.6 million for the nine months ended September 30, 2026, compared to $3.0 million in the corresponding period of 2025, primarily reflecting the continued expansion of the Company's U.S. commercial activities.
General and administrative expenses were $3.5 million for the nine months ended September 30, 2026, compared to $3.3 million in the corresponding period of 2025.
Operating loss for the nine months ended September 30, 2026 was $12.9 million, compared to $10.8 million in the corresponding period of 2025.
Net loss for the nine months ended September 30, 2026, was $12.9 million, compared to $10.8 million in the corresponding period of 2025.
As of September 30, 2026, the Company's cash and cash equivalents totaled approximately $8.2 million, and shareholders' equity was approximately $8.7 million.
Conference call & webcast info:
Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company's developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Relations:
Meir Peleg, CFO
[email protected]
+1-888-902-5716
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
As of
September 30,
2026
As of
December 31,
2025
(Unaudited)
U.S. dollars in thousands
ASSETS
CURRENT ASSETS
Cash and cash equivalents
8,220
8,897
Trade receivables
391
331
Inventory
2,578
2,625
Prepaid expenses and other receivables
1,298
752
Total current assets
12,487
12,605
NON-CURRENT ASSETS
Right-of-use assets
729
239
Property and equipment, net
940
993
Long-term restricted deposits
53
51
Total non-current assets
1,722
1,283
TOTAL ASSETS
14,209
13,888
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Trade payables
1,071
863
Lease liabilities
255
204
Employees and employees related benefits
3,024
2,659
Other current liabilities
633
1,098
Total current liabilities
4,983
4,824
NON-CURRENT LIABILITIES
Long-term lease liabilities
452
13
Total non-current liabilities
452
13
SHAREHOLDERS' EQUITY
Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and
outstanding: 5,563,265 shares and 2,437,410 shares as of September 30,
2026 and December 31, 2025, respectively
Additional paid-in capital
142,205
129,487
Accumulated deficit
(133,431)
(120,436)
Total shareholders' equity
8,774
9,051
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
14,209
13,888
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Nine months ended
September 30,
2026
2025
U.S. dollars in thousands
(except per share data)
Revenues
2,642
2,100
Cost of revenues
1,880
1,474
Gross profit
762
626
Research and development expenses
6,557
5,137
Sales and marketing expenses
3,669
3,061
General and administrative expenses
3,527
3,306
Operating loss
12,991
10,878
Finance expenses (income), net
4
(67)
Net loss and comprehensive loss
12,995
10,811
Basic and diluted net loss per share
3.57
5.4
Weighted average number of shares outstanding used in
computing basic and diluted loss per share
3,637,322
2,018,573
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine months ended
September 30,
2026
2025
U.S. dollars in
thousands
Cash flows from operating activities
Net loss
(12,995)
(10,811)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
207
224
Share-based compensation
687
1,102
Exchange rate changes in cash and cash equivalents and long-term restricted
deposits
(24)
118
Other finance cost
-
(34)
Changes in assets and liabilities:
Decrease (increase) in trade receivables
(60)
117
Decrease (increase) in prepaid expenses and other receivables
(546)
145
Decrease (increase) in inventory
47
(723)
Decrease in right of use assets
228
251
Increase (decrease) in trade payables
208
(81)
Decrease in lease liabilities
(227)
(212)
Increase in employees and employees related liabilities
365
595
Decrease in other current liabilities
(465)
(246)
Net cash used in operating activities
(12,575)
(9,555)
Cash flows from investing activities
Investment in short-term deposits
-
(5,000)
Purchase of property and equipment
(154)
(31)
Net cash used in investing activities
(154)
(5,031)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net
of issuance costs
12,020
12,114
Proceeds from exercise of warrants and pre-funded warrants
10
-
Net cash provided by financing activities
12,030
12,114
Decrease in cash and cash equivalents
(699)
(2,472)
Cash and cash equivalents at beginning of the year
8,897
7,564
Effect of exchange rate fluctuations on balances of cash and cash equivalents
22
(121)
Cash and cash equivalents at end of period
8,220
4,971
Non-cash activities
Obtaining a right-of-use asset in exchange for a lease liability
718
41
SOURCE IceCure Medical